CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company which has rapidly garnered a reputation and loyal following due to its innovative technology and proprietary product line, marketed through its Xceptol consumer brand. Founded in May 2017, CannAssist moved to the forefront of the cannabidiol industry following the passing of the 2018 Farm Bill, whereby the United States effectively decriminalized the cultivation and use of hemp and its derivative products. Since then, the global cannabidiol (“CBD”) industry has seen its growth and popularity surge to new heights, set to rise from a market value of $4.6 billion in 2018 to an estimated $23.6 billion by 2025 (https://ibn.fm/PL6PO).
In a sector which has seen its ranks rapidly swell given an influx of new entrants, CannAssist’s wholly owned Xceptor Labs has sought to differentiate itself through the use and development of its CiBiDinol technology. CiBiDinol technology is comprised of a proprietary process specifically designed to address a number of the shortcomings currently afflicting oil-soluble CBD molecules – namely, the delivery, bioavailability and short shelf-life (https://ibn.fm/GfbVM).
Through its unique formulations and technology, CannAssist has succeeded in developing CBD products offering a greater level of predictable potency while allowing for lower dosage requirements. By effectively covering the CBD molecule’s surface and rendering it water dispersible, CiBiDinol allows for more effective absorption of the product through the consumer’s skin and gut, which in turn significantly lowers the amount of CBD needed to achieve the product’s targeted endpoints.
Xceptor Labs has recently begun marketing its CiBiDinol technology-based Xceptol line of topical pain cream products as of September 2020. Comprising five creams which utilize FDA-registered ingredients and are designed to provide localized and fast-acting relief for sore and aching muscles and joints, the products are set to be sold online – through consumer products portal Range Me as well as through a network of international and domestic retail distributors. Meanwhile, the company is planning to raise awareness around the Xceptol product range through an upcoming series of targeted social media campaigns which will feature celebrities and former athletes advocating the product line’s various features. Xceptor Labs has recently added an array of CBD-based capsules, tinctures and pet drops.
CBD products have gained a reputation for their ability to provide medical relief under a variety of conditions while simultaneously excluding the psychoactive effects caused by tetrahydrocannabinol (“THC”). According to a study by the Harvard Health Institute in 2018, CBD products have been habitually used to address a wide gamut of health issues, including insomnia, anxiety, and physical pain, among various others. Meanwhile, increased legalization initiatives and growing consumer acceptance around the world have spurred further interest and innovation within the sector – a trend which CannAssist intends to lead.
Separately, CannAssist has recently revealed that based on the ongoing revenue trends from raw material and retail sales, and Xceptol’s international development, the company expects to generate sales of $5 million in first-year revenues.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective…
A team of researchers has leveraged a technique called temporal learning to train an AI…
Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year…
“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…
Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…
A new study focusing on twins has found that individuals with a larger presence of…